Zoya Demidenko: Scientist in Oncology Science Zoya Demidenko is a distinguished researcher connected with the Department of Cell Stress Research at Roswell Park Oncology Institute in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, establishing a solid foundation in clinical investigation.
Demidenko’s scientific output encompasses multiple key domains, among them the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cellular aging, and malignancy biology. Currently, she has co-authored over 46 academic papers, which have accumulated over 4,100 citations — a indicator to the significance of her work.
One of her most significant achievements lies in explaining the pathways of cell aging. Her work demonstrated that when the cellular division cycle is blocked but cellular growth proceeds, the cells undergo senescence. Significantly, Zoya Demidenko showed that this transition can be controlled with drugs using compounds such as rapamycin. Zoya Demidenko has also added considerably to oncological therapy research, particularly in the field of selective cell protection — a strategy intended to protecting normal cells from anticancer drugs whilst leaving tumor cells susceptible. This approach holds significant hope for diminishing the toxic effects of cancer treatment.
Across her scientific life, Demidenko has partnered with prominent researchers internationally, including Dr. Mikhail Blagosklonny. Her publications can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a highly impactful voice in current oncological science, with her findings go on to shape our comprehension of how cells age, resist treatment, and how malignant disease can be more effectively treated. https://www.aging-us.com/article/100406/
mostbet promo aksiya https://mostbet73618.help
mostbet казино приложение mostbet казино приложение
descarca 1win https://www.1win71038.help
Zoya Demidenko: Scientist in Oncology Science
Zoya Demidenko is a distinguished researcher connected with the Department of Cell Stress Research at Roswell Park Oncology Institute in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, establishing a solid foundation in clinical investigation.
Demidenko’s scientific output encompasses multiple key domains, among them the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cellular aging, and malignancy biology. Currently, she has co-authored over 46 academic papers, which have accumulated over 4,100 citations — a indicator to the significance of her work.
One of her most significant achievements lies in explaining the pathways of cell aging. Her work demonstrated that when the cellular division cycle is blocked but cellular growth proceeds, the cells undergo senescence. Significantly, Zoya Demidenko showed that this transition can be controlled with drugs using compounds such as rapamycin.
Zoya Demidenko has also added considerably to oncological therapy research, particularly in the field of selective cell protection — a strategy intended to protecting normal cells from anticancer drugs whilst leaving tumor cells susceptible. This approach holds significant hope for diminishing the toxic effects of cancer treatment.
Across her scientific life, Demidenko has partnered with prominent researchers internationally, including Dr. Mikhail Blagosklonny. Her publications can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a highly impactful voice in current oncological science, with her findings go on to shape our comprehension of how cells age, resist treatment, and how malignant disease can be more effectively treated.
https://www.aging-us.com/article/100406/
мостбет не приходит смс мостбет не приходит смс